Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07646210 iPSC derived cardiac muscle cell (Help Therapeutics) Heart Failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07646210 clinical trial report covering iPSC derived cardiac muscle cell (Help Therapeutics), Phase 1/2, endpoints, sponsor, geography, readout timing a
Latest Hotspot
8 min read
ChiCTR2600126711 Apatinib Mesylate Refractory Osteosarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126711 clinical trial report covering Apatinib Mesylate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647237 GR-2301 Vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647237 clinical trial report covering GR-2301, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07666750 EDV-01 Dysentery, Bacillary Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07666750 clinical trial report covering EDV-01, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07667387 LNP.UCD.ABE Carbamoyl-Phosphate Synthase I Deficiency Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07667387 clinical trial report covering LNP.UCD.ABE, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07678307 Autologous nano CD5-CAR T cells (Institute of Hematology & Blood Diseases Hospit Precursor T-cell lymphoblastic lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07678307 clinical trial report covering Autologous nano CD5-CAR T cells (Institute of Hematology & Blood Diseases Hospit, Phase 1/2, endpoints, sponsor,
Latest Hotspot
8 min read
NCT07714317 Sintilimab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07714317 clinical trial report covering Sintilimab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07714512 Isatuximab-IRFC Anemia, Aplastic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07714512 clinical trial report covering Isatuximab-IRFC, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07614828 Toripalimab Mucosal Melanoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07614828 clinical trial report covering Toripalimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07618624 Cetuximab Recurrent Squamous Cell Carcinoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07618624 clinical trial report covering Cetuximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07619937 Tislelizumab Locally Advanced Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07619937 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262028 HY-078020 Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262028 clinical trial report covering HY-078020, Phase 2, endpoints, sponsor, geography, readout timing and development white space.